Menin inhibition reported to induce CLEC12A and sensitise KMT2A-r and NPM1-mutant AML to CLEC12A-directed CAR cells (2026 preprint, not peer reviewed)
also called epigenetic priming of CLEC12A · menin inhibitor plus CLL-1 CAR · revumenib CLEC12A induction
A 2026 preprint reports that menin inhibitors - the drugs at the centre of this project - turn on a surface protein called CLEC12A on leukaemia cells, which makes a CLEC12A-targeting cell therapy work much better. If it survives peer review, it turns a drug we already use into a way of creating a target that was not there before.
The same thing, for a scientist
Rausch and colleagues (preprint, February 2026) report that menin inhibition **induces robust and uniform CLEC12A expression** in *KMT2A*-rearranged and *NPM1*-mutated AML, that menin inhibitors do not impair T or NK cell viability, phenotype or effector function, and that second-generation CLEC12A-directed CAR T cells combined with menin inhibition outperform either monotherapy across in vitro systems and xenograft models, with near-complete leukaemia eradication in vivo [E1]. **Why this matters more than an ordinary combination result.** Every menin-inhibitor combination in this graph so far is a *killing* combination - add a second cytotoxic pressure. This is a **target-creation** claim: the epigenetic drug's job is to make the antigen appear. That is a qualitatively different mechanism and it has a specific, testable failure mode that a killing combination does not have. **And it lands on a live clinical problem.** KITE-222, a CLL-1-directed CAR T, produced no clinically meaningful responses in 12 R/R AML patients precisely because **CLL-1-negative blasts persisted** after CLL-1-positive blasts were cleared [E2]. Antigen heterogeneity is the documented reason CLEC12A monotherapy failed. An agent that makes the antigen uniform is aimed exactly at that failure - which is what makes the preprint interesting and also what makes uncritical acceptance dangerous. **Status: weak.** Not peer reviewed; Europe PMC reports no PMID, no PMCID and `isOpenAccess: N`, so only the abstract and significance statement were read. Nothing about magnitude, kinetics, dose-dependence, the number of models, or whether the induction is transcriptional at the *CLEC12A* locus is known to this entry.
The mechanism as claimed, and the three things that are not established
As claimed. Menin inhibitor -> disruption of the Menin-KMT2A chromatin complex -> induction of CLEC12A -> uniform surface CLEC12A -> CLEC12A-CAR engagement -> killing. The authors call it epigenetic priming.
Not established by anything read here:
- Directness. Is CLEC12A a direct target of the Menin-KMT2A complex, or does it come up because menin inhibition drives myeloid differentiation and CLEC12A is a differentiation antigen? Macher 1990 and Paietta 2003 both establish that myeloid surface antigens track maturation stage [see
target-cd15-lewis-x,target-cd65s-sialylated-vim2-ganglioside], and CLEC12A is on mature granulocytes and monocytes. If the induction is a differentiation read-out, any differentiating agent should reproduce it, and the synergy is not menin-specific. - Whether it survives the resistance route this graph already tracks. Menin-inhibitor resistance via MEN1 mutation restores the complex. A clone that is menin-inhibitor-resistant would, on this mechanism, also be CLEC12A-non-induced, so the CAR loses its target in the same clone that escapes the drug. The two arms would share a resistance mechanism rather than covering for one another. Nothing in the abstract addresses this.
- Whether it applies to B-lineage KMT2A-r disease. The preprint is AML (KMT2A-r and NPM1-mutated). The index disease of this project is infant KMT2A-rearranged B-ALL, where CLEC12A is rare at baseline [
gene-clec12a] and where there is no measurement of menin-inhibitor-induced CLEC12A at all.
What would have to be true for this to change clinical practice
- The induction must be large enough and uniform enough to convert the CLL-1-negative blast fraction that persisted in KITE-222 2. A two-fold mean shift that leaves a negative tail does not solve the problem that killed that trial.
- The induction must persist long enough for CAR engagement, given that menin inhibitors are dosed continuously and CAR expansion peaks within about two weeks [see
gene-clec12aE7]. - The T cells must be unharmed, which the preprint asserts 1 and which is a checkable claim that peer review should test directly.
- The induction must occur in patient blasts, not only in lines and xenografts.
| mechanism class | transcriptional induction of a surface antigen by an epigenetic inhibitor (claimed) |
|---|---|
| upstream | Menin-KMT2A chromatin complex inhibition |
| readout | uniform surface CLEC12A; sensitisation to CLEC12A-directed CAR T and NK cells |
| models | in vitro systems and xenograft models (numbers not available at abstract level) |
| peer reviewed | false |
| preprint ID | PPR1223455 |
| clinical problem addressed | CLL-1-negative blast persistence that defeated KITE-222 (PMID 41941266) |
- **Shared resistance.** If induction requires an intact menin-inhibitor response, then the clone that escapes the menin inhibitor is simultaneously invisible to the CAR. The combination may be two arms with one failure mode.
- **Inducing an antigen on normal myeloid cells too.** Menin inhibitors act on normal haematopoiesis as well. If CLEC12A is induced on normal progenitors or on recovering myeloid cells, the combination widens the on-target/off-tumour window in the wrong direction - and the untreated baseline is already a target on all granulocytes and monocytes.
- **Differentiation syndrome plus CAR cytokine release.** Menin inhibitors carry a documented differentiation-syndrome risk and CAR T cells carry CRS. Combining an agent that drives myeloid differentiation with one that triggers cytokine release has an additive-toxicity hypothesis that the preprint's abstract does not address.
- **A preprint is not a result.** This entry is `weak` and `status: verified` only in the sense that the identifier resolves to the document it names. No claim in it should enter a protocol before peer review and full-text reading.
- Is the CLEC12A induction a direct chromatin effect at the *CLEC12A* locus or a downstream consequence of menin-inhibitor-driven myeloid differentiation? A ChIP or CUT&RUN for the fusion and for menin at *CLEC12A*, plus a comparison against a non-menin differentiating agent, separates them.
- Do *MEN1*-mutant menin-inhibitor-resistant clones fail to induce CLEC12A? If so the combination has one shared resistance mechanism, not two independent ones, and its apparent synergy would not survive relapse.
- Does the induction occur in KMT2A-rearranged B-lineage blasts, where baseline CLEC12A is rare? Nothing in this graph measures it.
- Would a differentiating agent already licensed in this disease reproduce the induction more cheaply than a menin inhibitor?
- E1weak confidence 2 of 5: Preliminary, small, indirect, or not yet peer reviewed.preprint
A 2026 preprint reports that menin inhibition primes KMT2A-rearranged and NPM1-mutated AML for CAR-based targeting by inducing robust and uniform expression of CLEC12A; that menin inhibitors did not impair T or NK cell viability, phenotype or effector function; and that second-generation CLEC12A-directed CAR T cells combined with menin inhibition consistently outperformed either monotherapy across in vitro systems and xenograft models, with evidence of near-complete leukaemia eradication in vivo.
Menin-Inhibition Sensitizes Acute Myeloid Leukemia to CLEC12A-Directed CAR Cell Therapy · Rausch J, Wendel P, Dzama-Karels M, Steiner M, Gierschek F, Fetsch V, et al. · Preprint, not peer reviewed (Europe PMC PPR1223455) 2026What this evidence cannot show
**Preprint, not peer reviewed.** Identified and read on 2026-09-20 from the Europe PMC core record for PPR1223455; the DOI 10.64898/2026.02.15.703376, the title, the author string and the abstract were all copied out of that one fetched record. Europe PMC gives no PMID and no PMCID and reports `isOpenAccess: N`, so full text was not retrieved and **no quantitative claim in this entry comes from the paper's data - only from its abstract and significance statement**. Confidence is `weak` because the claim is unreviewed and read at abstract level only.
Evidence that argues against this (1)
- The peer-reviewed paediatric AML immunotarget survey reaches the opposite operational conclusion for the KMT2A subgroup: KMT2A-mutated infant AML clustered separately and overexpressed FLT3, and the authors nominate CD33/FLT3 co-targeting for that subgroup rather than CLEC12A. The two are reconcilable only if menin inhibition changes the baseline that survey measured. Willier S et al. 2021
- E2strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.paper
In the phase 1 study of KITE-222, a CLL-1-directed CAR T-cell therapy in 12 patients with relapsed/refractory AML, clinically meaningful responses were lacking across dose levels despite detectable CAR T-cell expansion, and in two of five cohort-3 patients with clear expansion CLL-1-positive marrow blasts were nearly completely depleted while CLL-1-negative blasts persisted and total blasts did not fall; the authors conclude that future studies must address CLL-1 heterogeneity.
Phase 1 Study of KITE-222, an Autologous CLL-1-Directed CAR T-cell Therapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia. · Daver N, Blachly JS, Ghobadi A, Advani A, Muffly L, Garciaz S, et al. · Clin Cancer Res 2026What this evidence cannot show
Abstract read in full from raw NCBI efetch XML on 2026-09-20; full text not read. n=12 dose escalation in adult R/R AML; no menin inhibitor was given, so this trial is the uncombined comparator the preprint's proposal would have to beat, not a test of it. No paediatric or KMT2A-rearranged patients described in the abstract.
Evidence that argues against this (1)
- The trial also reports an acceptable safety profile with no grade >=3 CRS, so its negative result is about efficacy and antigen coverage, not about CLEC12A being an unsafe target. Reading it as 'CLEC12A does not work' overstates it; the authors read it as 'CLL-1 heterogeneity must be addressed', which is what the induction strategy claims to do. Xiu Y et al. 2018
- E3strong confidence 4 of 5: Replicated in peer-reviewed work by more than one group.dataset
As of 2026-09-20, PubMed returns 2 records for `CLEC12A AND (KMT2A OR MLL)`, and Europe PMC free-text returns 142; of the 74 Europe PMC records matching `CLEC12A AND (KMT2A OR MLL) AND (knockout OR CRISPR OR dependency)`, exactly 2 have titles naming CLEC12A or any of its aliases, and neither is a menin-inhibitor/CLEC12A study other than the preprint itself.
Q48 surface-antigen beat: bounded counted-absence sweep, PubMed E-utilities and Europe PMC REST · Q48-surface-antigens · Oncofusion knowledge graph (internal measurement, 2026-09-20) 2026What this evidence cannot show
**Rule 67 controls run through the identical code path on 2026-09-20 before any zero was recorded:** PubMed `CLEC12A` = 156, `KMT2A OR MLL` = 9,229, `CLEC12A AND leukemia` = 54; Europe PMC `CLEC12A` = 1,361. All controls return large non-zero counts, so the instrument demonstrably returns ones. The Europe PMC counts are **full-text** co-mention counts and are not comparable to PubMed's title/abstract/MeSH counts; the 74 were title-checked, not read, so a menin/CLEC12A result buried in a body text without a naming title would be missed. The PubMed query was run unparenthesised except for the OR group and `querytranslation` was read back for each.
Evidence that argues against this (1)
- A literature count taken on one day cannot establish that a claim is novel, only that it is not indexed under these strings today. The preprint itself was found through Europe PMC and not PubMed, which demonstrates the gap: a PubMed-only sweep would have returned a clean, wrong negative for the central finding of this beat. Q48-surface-antigens 2026
the preprint reports menin inhibitors do not impair NK viability or effector function
the clearest target-creation case, and therefore the clearest case for a lead-in
the drug-induced antigen route this entry contrasts with a fusion-driven one
menin inhibition reported to induce robust and uniform CLEC12A expression (preprint)
the mechanism requires an intact menin-inhibitor response, which is what MEN1 resistance mutations remove
menin inhibitor class; the preprint does not name a single agent at abstract level
claimed in KMT2A-rearranged and NPM1-mutated AML
CLEC12A-directed CAR T and NK cells are the effector arm of the claimed combination
the only proposal in this graph for creating rather than exploiting an antigen
inducing the antigen may widen the on-target/off-tumour overlap onto normal myeloid cells